[go: up one dir, main page]

HK1219043A1 - 具有毒蕈鹼受體拮抗劑和 腎上腺素受體激動劑活動性的 -氨基- -羥乙基- -羥基喹啉- -酮衍生物的鹽 - Google Patents

具有毒蕈鹼受體拮抗劑和 腎上腺素受體激動劑活動性的 -氨基- -羥乙基- -羥基喹啉- -酮衍生物的鹽

Info

Publication number
HK1219043A1
HK1219043A1 HK16106791.0A HK16106791A HK1219043A1 HK 1219043 A1 HK1219043 A1 HK 1219043A1 HK 16106791 A HK16106791 A HK 16106791A HK 1219043 A1 HK1219043 A1 HK 1219043A1
Authority
HK
Hong Kong
Prior art keywords
hydroxyquinolin
hydroxyethyl
derivatives
salts
amino
Prior art date
Application number
HK16106791.0A
Other languages
English (en)
Inventor
Jane Montserrat Julia
Carrera Francesc Carrera
Quinones Maria Prat
Duran Carlos Puig
Lorenzo Francesca Pajuelo
Andres Juan Antonio Perez
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of HK1219043A1 publication Critical patent/HK1219043A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16106791.0A 2013-07-25 2016-06-13 具有毒蕈鹼受體拮抗劑和 腎上腺素受體激動劑活動性的 -氨基- -羥乙基- -羥基喹啉- -酮衍生物的鹽 HK1219043A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382304 2013-07-25
PCT/EP2014/065965 WO2015011244A1 (en) 2013-07-25 2014-07-24 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES

Publications (1)

Publication Number Publication Date
HK1219043A1 true HK1219043A1 (zh) 2017-03-24

Family

ID=48917474

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106791.0A HK1219043A1 (zh) 2013-07-25 2016-06-13 具有毒蕈鹼受體拮抗劑和 腎上腺素受體激動劑活動性的 -氨基- -羥乙基- -羥基喹啉- -酮衍生物的鹽

Country Status (37)

Country Link
US (1) US9579316B2 (zh)
EP (1) EP3024489B1 (zh)
JP (1) JP6374962B2 (zh)
KR (1) KR102338155B1 (zh)
CN (2) CN105492027A (zh)
AR (1) AR097079A1 (zh)
AU (1) AU2014295028B2 (zh)
BR (1) BR112016001295B1 (zh)
CA (1) CA2917596C (zh)
CL (1) CL2016000187A1 (zh)
CR (1) CR20160043A (zh)
CY (1) CY1122920T1 (zh)
DK (1) DK3024489T3 (zh)
DO (1) DOP2016000011A (zh)
EA (1) EA035436B1 (zh)
ES (1) ES2788627T3 (zh)
HK (1) HK1219043A1 (zh)
HR (1) HRP20200670T1 (zh)
HU (1) HUE049441T2 (zh)
IL (1) IL243173B (zh)
LT (1) LT3024489T (zh)
MX (1) MX360837B (zh)
MY (1) MY184681A (zh)
NI (1) NI201600012A (zh)
NZ (1) NZ715128A (zh)
PE (1) PE20160173A1 (zh)
PH (1) PH12016500125B1 (zh)
PL (1) PL3024489T3 (zh)
PT (1) PT3024489T (zh)
RS (1) RS60185B1 (zh)
SG (1) SG11201510682YA (zh)
SI (1) SI3024489T1 (zh)
SM (1) SMT202000185T1 (zh)
TW (1) TWI641373B (zh)
UY (1) UY35678A (zh)
WO (1) WO2015011244A1 (zh)
ZA (1) ZA201509203B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
TW201517906A (zh) * 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
US20190185461A1 (en) * 2015-07-21 2019-06-20 Sichuan Haisco Pharmaceutical Co., Ltd. Benzocyclic derivative having b2-receptor agonist activity and m3-receptor antagonist activity and medical use thereof
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
TW201835041A (zh) * 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
WO2020244452A1 (zh) * 2019-06-06 2020-12-10 中国医药研究开发中心有限公司 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
CN117534663A (zh) * 2020-09-28 2024-02-09 正大天晴药业集团股份有限公司 稠合的三并环衍生物及其在药学上的应用
EP4501927A1 (en) * 2022-03-25 2025-02-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of fused tricyclic derivative or pharmaceutically acceptable salt thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
DE3370320D1 (en) 1983-09-26 1987-04-23 Magis Farmaceutici Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
EP0416925A3 (en) 1989-09-07 1991-09-25 Glaxo Group Limited Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
AU4248597A (en) 1996-09-06 1998-03-26 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
ATE397590T1 (de) 1999-08-20 2008-06-15 Dow Agrosciences Llc Fungizide heterocyclische aromatische amide und deren zusammensetzungen, verfahren zu deren anwendung und herstellung
US6806314B2 (en) 2003-02-03 2004-10-19 Ppg Industries Ohio, Inc. Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
CA2643097C (en) 2006-03-20 2012-03-13 Pfizer Limited Amine derivatives
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
RS20090137A (en) 2006-10-04 2010-06-30 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
UY31235A1 (es) 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
BRPI0908353B8 (pt) 2008-02-06 2021-05-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
KR20110022611A (ko) * 2008-06-20 2011-03-07 아스트라제네카 아베 베타２－아드레날린수용체 활성의 조절을 위한, ４－히드록시－２－옥소－２,３－디히드로－１,３－벤조티아졸－７－일 화합물을 포함하는 제약 조성물
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
PL2421849T3 (pl) 2009-04-23 2013-08-30 Theravance Inc Związki diamidowe wykazujące aktywność antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta2
KR20120061061A (ko) 2009-04-30 2012-06-12 데이진 화-마 가부시키가이샤 4 급 암모늄염 화합물
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
WO2012168349A1 (en) 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ME02297B (me) 2011-06-10 2016-02-20 Chiesi Farm Spa Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
GEP201706656B (en) 2011-11-11 2017-04-25 Pfizer 2-thiopyrimidinones
EA033598B1 (ru) 2011-11-11 2019-11-07 Gilead Apollo Llc Ингибиторы асс и их применения
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
PL2928890T3 (pl) 2012-12-06 2018-07-31 Chiesi Farmaceutici S.P.A. Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
EP2928889B1 (en) 2012-12-06 2018-03-21 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
TW201517907A (zh) 2015-05-16
CR20160043A (es) 2016-04-08
AU2014295028A1 (en) 2016-01-21
LT3024489T (lt) 2020-03-10
MX2016000397A (es) 2016-04-29
JP6374962B2 (ja) 2018-08-15
BR112016001295B1 (pt) 2022-07-19
AU2014295028B2 (en) 2018-05-31
CY1122920T1 (el) 2021-10-29
SI3024489T1 (sl) 2020-04-30
EP3024489B1 (en) 2020-02-19
TWI641373B (zh) 2018-11-21
WO2015011244A1 (en) 2015-01-29
MX360837B (es) 2018-11-20
RS60185B1 (sr) 2020-06-30
KR20160034310A (ko) 2016-03-29
UY35678A (es) 2015-02-27
EP3024489A1 (en) 2016-06-01
PH12016500125A1 (en) 2016-04-25
CN112321579A (zh) 2021-02-05
PL3024489T3 (pl) 2020-08-10
CL2016000187A1 (es) 2016-08-05
DOP2016000011A (es) 2016-06-15
SG11201510682YA (en) 2016-02-26
EA035436B1 (ru) 2020-06-15
ZA201509203B (en) 2017-04-26
AR097079A1 (es) 2016-02-17
KR102338155B1 (ko) 2021-12-10
CA2917596C (en) 2021-06-22
NZ715128A (en) 2019-03-29
SMT202000185T1 (it) 2020-05-08
IL243173B (en) 2019-10-31
NI201600012A (es) 2016-10-10
PT3024489T (pt) 2020-05-05
HRP20200670T1 (hr) 2020-07-10
EA201600128A1 (ru) 2016-07-29
IL243173A0 (en) 2016-02-29
DK3024489T3 (da) 2020-05-04
PH12016500125B1 (en) 2016-04-25
PE20160173A1 (es) 2016-04-13
JP2016525533A (ja) 2016-08-25
CN105492027A (zh) 2016-04-13
MY184681A (en) 2021-04-16
ES2788627T3 (es) 2020-10-22
CA2917596A1 (en) 2015-01-29
US20160166566A1 (en) 2016-06-16
HUE049441T2 (hu) 2020-09-28
BR112016001295A2 (zh) 2017-07-25
US9579316B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
HK1219043A1 (zh) 具有毒蕈鹼受體拮抗劑和 腎上腺素受體激動劑活動性的 -氨基- -羥乙基- -羥基喹啉- -酮衍生物的鹽
HK1212246A1 (zh) 具有β 腎上腺素能受體激動劑和 毒蕈碱受體拮抗劑兩種活性的 -氨基- -羥乙基- -羥基喹啉- -銅衍生物的鹽
HRP20180915T1 (hr) Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
HK1212987A1 (zh) 具有毒蕈鹼受體拮抗劑和β 腎上腺素能受體激動劑活性的化合物
IL253922A0 (en) Compounds with muscarinic receptor antagonist and adrenergic receptor agonist activity in cell 2
IL232477A (en) Cyclohexylamine derivatives with the activity of beta 2-adrenergic agonist and 3m muscarinic antagonist
GB201321089D0 (en) Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
TH1601000390A (th) เกลือของอนุพันธ์ 2-อะมิโน-1-ไฮดรอกซีเอทริล-8-ไฮดรอกซีควิโนลิน-2-(1H)-โอน(2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one) ซึ่งมีทั้งฤทธิ์มัสคารินิก รีเซพเตอร์แอนทาโกนิสและฤทธิ์ (เบต้า)2 อะดรีเนอร์จิกรีเซพเตอร์อะโกนิสต์

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240726